A Phase 1 interventional study of Idelalisib and Nab-paclitaxel in Previously Untreated Pancreatic Ductal Adenocarcinoma and Relapsed/Refractory Pancreatic Ductal Adenocarcinoma, sponsored by Gilead Sciences. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-02.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
The presence of pancreatic adenocarcinoma plus 1 of the following:
Adequate organ function defined as follows:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
Drug: Idelalisib
Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
Drug: Idelalisib · Drug: Nab-paclitaxel
Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
Drug: Idelalisib · Drug: mFOLFOX6
Tablets administered orally twice daily
Also known as: GS-1101, CAL-101, Zydelig®
125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
TEAEs were defined as adverse events (AEs) with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the study drug. It also included the AEs that led to premature discontinuation of study drug.
Time frame: First dose date up to last dose date (Maximum: 8 weeks) plus 30 days
Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post baseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Severity grade is defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening). The percentage of participants for any post-baseline abnormal laboratory value in the Grade 1-4 category is reported. The term 'hypo' indicates less than the normal count of a parameter and 'hyper' indicates more than the normal count of a parameter.
Time frame: First dose date up to last dose date (Maximum: 8 weeks) plus 30 days
Idelalisib in Combination With Chemotherapy: Percentage of Participants With Dose Limiting Toxicities (DLTs)
Dose limiting toxicities were defined as toxicities experienced during the first 28 days of treatment (Cycle 1) that were judged to be clinically significant and at least possibly related to study treatment.
Time frame: Up to 28 days
Change From Baseline in FoxP3+ and Cluster Determinant 8+ (CD8+) Cells From Tumor Tissue Samples as a Measure of Pharmacodynamics Activity
Time frame: Up to 2 years
Idelalisib Plasma Concentrations Following Idelalisib 150 mg Twice Daily
Time frame: Cycle 1, Day 1: Predose and 0.5, 1, 1.5, 2, 3, 4, and 8 hours (h) postdose; Day 8: Predose and 1.5 h postdose; Day 15: Predose and 1.5 h postdose Cycle 2, Day 1: Predose and 1.5 h postdose
Idelalisib Metabolite (GS-563117) Plasma Concentrations Following Idelalisib 150 mg Twice Daily
Time frame: Cycle 1, Day 1: Predose and 0.5, 1, 1.5, 2, 3, 4, and 8 h postdose; Day 8: Predose and 1.5 h postdose; Day 15: Predose and 1.5 h postdose Cycle 2, Day 1: Predose and 1.5 h postdose
Overall Response Rate (ORR)
Overall response rate (ORR) was defined as the percentage of participants who achieved a Complete Response (CR) or Partial Response (PR) as assessed by response evaluation criteria in sold tumors (RECIST) v1.1.
Time frame: Up to 2 years
Overall Survival (OS)
Overall survival is defined as the interval from first dose date of study drug to death from any cause.
Time frame: Up to 2 years
Progression Free Survival (PFS)
Progression free survival is defined as the interval from first dose date of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.
Time frame: Up to 2 years
Participants were enrolled at study sites in the United States. The first participant was screened on 30 July 2015. The last study visit occurred on 27 April 2016.
| Milestone | Idelalisib 150 mg |
|---|---|
| Started | 16 |
| Completed | 0 |
| Not completed | 16 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 1 |
| Withdrew: Study terminated by sponsor, regulatory agency or institutional review board/ ethics committee | 10 |
| Withdrew: All enrolled but never dosed | 4 |
TEAEs were defined as adverse events (AEs) with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the study drug. It also included the AEs that led to premature discontinuation of study drug.
| percentage of participants | Idelalisib 150 mg |
|---|---|
| Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) | 100.0 |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post baseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Severity grade is defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening). The percentage of participants for any post-baseline abnormal laboratory value in the Grade 1-4 category is reported. The term 'hypo' indicates less than the normal count of a parameter and 'hyper' indicates more than the normal count of a parameter.
| percentage of participants | Idelalisib 150 mg |
|---|---|
| Hemoglobin (Hypo), Hematology | 25.0 |
| Lymphocytes (Hyper), Hematology | 8.3 |
| Lymphocytes (Hypo), Hematology | 25.0 |
| Platelets, Hematology | 8.3 |
| Alanine Aminotransferase, Chemistry | 58.3 |
| Albumin, Chemistry | 16.7 |
| Alkaline Phosphatase, Chemistry | 33.3 |
| Aspartate Aminotransferase, Chemistry | 66.7 |
| Bilirubin, Chemistry | 16.7 |
| Creatinine Clearance, Chemistry | 16.7 |
| Gamma Glutamyl Transferase, Chemistry | 50.0 |
| Glucose (Hyper), Chemistry | 16.7 |
| Sodium (Hypo), Chemistry | 25.0 |
Dose limiting toxicities were defined as toxicities experienced during the first 28 days of treatment (Cycle 1) that were judged to be clinically significant and at least possibly related to study treatment.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| ng/mL | Idelalisib 150 mg |
|---|---|
| Cycle 1; Day 1 (Predose) | NA (NA to NA) |
| Cycle 1; Day 1 (0.5 h) | 1110 (13.90 to 3220) |
| Cycle 1; Day 1 (1 h) | 1880 (39.10 to 4060) |
| Cycle 1; Day 1 (1.5 h) | 1690 (318 to 2260) |
| Cycle 1; Day 1 (2 h) | 1290 (173 to 4460) |
| Cycle 1; Day 1 (3 h) | 795 (631 to 2870) |
| Cycle 1; Day 1 (4 h) | 1540 (519 to 1990) |
| Cycle 1; Day 1 (8 h) | 251 (134 to 753) |
| Cycle 1; Day 8 (Predose) | 264 (208 to 501.5) |
| Cycle 1; Day 8 (1.5 h) | 2050 (1335 to 2620) |
| Cycle 1; Day 15 (Predose) | 275 (241 to 1120) |
| Cycle 1; Day 15 (1.5 h) | 1605 (1170 to 2130) |
| Cycle 2; Day 1 (Predose) | 178.05 (39.05 to 281) |
| Cycle 2; Day 1 (1.5 h) | 2180 (1825 to 3095) |
| ng/mL | Idelalisib 150 mg |
|---|---|
| Cycle 1; Day 1 (Predose) | NA (NA to NA) |
| Cycle 1; Day 1 (0.5 h) | 173 (NA to 220) |
| Cycle 1; Day 1 (1 h) | 1220 (16.70 to 1460) |
| Cycle 1; Day 1 (1.5 h) | 1070 (141 to 1930) |
| Cycle 1; Day 1 (2 h) | 1700 (106 to 4430) |
| Cycle 1; Day 1 (3 h) | 1580 (190 to 5980) |
| Cycle 1; Day 1 (4 h) | 1370 (849 to 5960) |
| Cycle 1; Day 1 (8 h) | 632 (619 to 5340) |
| Cycle 1; Day 8 (Predose) | 2175 (1385 to 5790) |
| Cycle 1; Day 8 (1.5 h) | 2775 (1765 to 5725) |
| Cycle 1; Day 15 (Predose) | 2130 (1020 to 6800) |
| Cycle 1; Day 15 (1.5 h) | 2890 (2010 to 4815) |
| Cycle 2; Day 1 (Predose) | 1046.5 (490.34 to 1360) |
| Cycle 2; Day 1 (1.5 h) | 1405 (1325 to 2305) |
Overall response rate (ORR) was defined as the percentage of participants who achieved a Complete Response (CR) or Partial Response (PR) as assessed by response evaluation criteria in sold tumors (RECIST) v1.1.
No measurements were reported for this outcome.
Overall survival is defined as the interval from first dose date of study drug to death from any cause.
No measurements were reported for this outcome.
Progression free survival is defined as the interval from first dose date of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.
No measurements were reported for this outcome.
Collected over Adverse Events: First dose date up to last dose date (Maximum: 8 weeks) plus 30 days All-cause mortality: First dose date up to study termination (approximately 39 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib 150 mg | 2/12 (16.7%) | 3/12 (25%) | 12/12 (100%) |
| Event | Idelalisib 150 mg |
|---|---|
| CoagulopathyBlood and lymphatic system disorders | 1/12 |
| Small intestinal obstructionGastrointestinal disorders | 1/12 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/12 |
| PyrexiaGeneral disorders | 1/12 |
| Alanine aminotransferase increasedInvestigations | 1/12 |
| Aspartate aminotransferase increasedInvestigations | 1/12 |
| DehydrationMetabolism and nutrition disorders | 1/12 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/12 |
| Acute kidney injuryRenal and urinary disorders | 1/12 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/12 |
| Event | Idelalisib 150 mg |
|---|---|
| PyrexiaGeneral disorders | 5/12 |
| Aspartate aminotransferase increasedInvestigations | 4/12 |
| Alanine aminotransferase increasedInvestigations | 3/12 |
| Abdominal painGastrointestinal disorders | 2/12 |
| ConstipationGastrointestinal disorders | 2/12 |
| VomitingGastrointestinal disorders | 2/12 |
| ChillsGeneral disorders | 2/12 |
| InsomniaPsychiatric disorders | 2/12 |
| HaematuriaRenal and urinary disorders | 2/12 |
| RashSkin and subcutaneous tissue disorders | 2/12 |
The Full Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Idelalisib 150 mg |
|---|---|
| Mean | 62 ± 10.7 |
| Sex: Female, Male(Participants) | Idelalisib 150 mg |
|---|---|
| Female | 6 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Idelalisib 150 mg |
|---|---|
| Race — American Indian or Alaska Native | 0 |
| Race — Asian | 0 |
| Race — Black | 1 |
| Race — Native Hawaiian or Pacific Islander | 0 |
| Race — White | 11 |
| Race — Other | 0 |
| Race — Not Permitted | 0 |
| Race/Ethnicity, Customized(Participants) | Idelalisib 150 mg |
|---|---|
| Ethnicity — Hispanic or Latino | 0 |
| Ethnicity — Not Hispanic or Latino | 12 |
| Ethnicity — Not Permitted | 0 |
Ran from Jul 2015 to primary completion in Apr 2016, 8 months.
Results were first posted in Mar 2021, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib